ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021
Production of a Promising Biosynthetic Self-Assembled Nanoconjugate Vaccine against Klebsiella Pneumoniae Serotype O2 in a General Escherichia Coli Host.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Article
- Modular Development of aNanomaterials (Basel, Switzerland) · 2026Article
- Current Scientific Advances in Vaccines Against UTIs: Challenges and Prospects.Microorganisms · 2025Review
- Development of a Promising Bivalent Vaccine AgainstExploration (Beijing, China) · 2025Article
- Modular assembly and immunological evaluation of a promising bioconjugate nanovaccine against Klebsiella pneumoniae O2 serotype.NPJ vaccines · 2025Article
- Biosynthesis of Two Types of Exogenous Antigenic Polysaccharides in a SingleLife (Basel, Switzerland) · 2025Article
- Antimicrobial resistance and vaccines in Enterobacteriaceae including extraintestinal pathogenic Escherichia coli and Klebsiella pneumoniae.npj antimicrobials and resistance · 2025Review
- Antibody responses in Klebsiella pneumoniae bloodstream infection: a prospective cohort study.The Lancet. Microbe · 2025Article
- Exploring current hypervirulentFrontiers in microbiology · 2025Review
- Semisynthetic Glycoconjugate Vaccine Lead againstJournal of the American Chemical Society · 2024Article
- Review
- Heptavalent O-Antigen Bioconjugate Vaccine Exhibiting Differential Functional Antibody Responses Against Diverse Klebsiella pneumoniae Isolates.The Journal of infectious diseases · 2024Article
- Efficient Production of Self-Assembled Bioconjugate Nanovaccines againstNanomaterials (Basel, Switzerland) · 2024Article
- Impact of Protein Nanoparticle Shape on the Immunogenicity of Antimicrobial Glycoconjugate Vaccines.International journal of molecular sciences · 2024Article
- Article
- A heptavalent O-antigen bioconjugate vaccine exhibits differential functional antibody responses against diversebioRxiv : the preprint server for biology · 2023Article
- Article
- Genetic Engineering ofMicroorganisms · 2023Article
- Preparation of a Klebsiella pneumoniae conjugate nanovaccine using glycol-engineered Escherichia coli.Microbial cell factories · 2023Article
- Capsular polysaccharide inhibits vaccine-induced O-antigen antibody binding and function across both classical and hypervirulent K2:O1 strains of Klebsiella pneumoniae.PLoS pathogens · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Klebsiella pneumoniae has emerged as a severe opportunistic pathogen with multiple drug resistances. Finding effective vaccines against this pathogen is urgent. Although O-polysaccharides (OPS) of K. pneumoniae are suitable antigens for the preparation of vaccines given their low levels of diversity, the low immunogenicity (especially serotype O2) limit their application. In this study, a general Escherichia coli host system is developed to produce a nanoscale conjugate vaccine against K. pneumoniae using the Nano-B5 self-assembly platform. The experimental data illustrate that this nanoconjugate vaccine can induce an efficient humoral immune response in draining lymph nodes (dLNs) and elicit high titers of the IgG antibody against bacterial lipopolysaccharide (LPS). The ideal prophylactic effects of these nanoconjugate vaccines are further demonstrated in mouse models of both systemic and pulmonary infection. These results demonstrate that OPS with low immunogenicity can be changed into an effective antigen, indicating that other haptens may be applicable to this strategy in the future. To the knowledge, this is the first study to produce biosynthetic nanoconjugate vaccines against K. pneumoniae in E. coli, and this strategy can be applied to the development of other vaccines against pathogenic bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.